Boundless Bio, Inc.（BOLD）の財務BOLDBoundless Bio, Inc.

Evaluating the bottom line, Boundless Bio, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -67.86%, provide a clear picture of how effectively BOLD converts its operational activities into shareholder value.

In the context of the broader market, BOLD competes directly with industry leaders such as XBIT and NMAD. With a market capitalization of $56.85M, it holds a significant position in the sector. When comparing efficiency, BOLD's gross margin of N/A stands against XBIT's N/A and NMAD's N/A. Such benchmarking helps identify whether Boundless Bio, Inc. is trading at a premium or discount relative to its financial performance.

The company has been experiencing significant losses, with net income consistently negative, reaching -23,693,000 USD in Q2 2026. The current ratio remains strong at 9.48, indicating good short-term liquidity despite the losses.